On June 7, 2023 Ascendis Pharma A/S (Nasdaq: ASND) reported that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13 (Press release, Ascendis Pharma, JUN 7, 2023, View Source [SID1234632550]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details:

Event Goldman Sachs 44th Annual Global Healthcare Conference
Location Dana Point, CA
Date Tuesday, June 13, 2023
Time 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time
A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at View Source A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.

On June 7, 2023 Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company, reported that it has launched an underwritten public offering of shares of its common stock (the "Offering") (Press release, Akoya Biosciences, JUN 7, 2023, View Source [SID1234632549]). In addition, Akoya expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Akoya intends to use the net proceeds from the Offering for working capital and general corporate purposes.

Morgan Stanley and Piper Sandler, are acting as joint book-running managers for the Offering.

The securities described above are being offered by Akoya pursuant to a shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on November 21, 2022. A preliminary prospectus supplement and the accompanying prospectus relating to the Offering will be filed by Akoya with the SEC and will be available on the SEC’s website at www.sec.gov. A final prospectus supplement and the accompanying prospectus relating to the Offering will be filed by Akoya with the SEC. The Offering will be made only by means of a prospectus, including a prospectus supplement, that forms part of the registration statement referred to above. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the Offering may be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone at 1-866-718-1649 or by email at [email protected] and Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Maill J12S03, Minneapolis, Minnesota 55402, by telephone at 1-800-747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On June 7, 2023 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, reported that members of the management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 6:20pm ET in Dana Point, CA (Press release, 2seventy bio, JUN 7, 2023, View Source [SID1234632548]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available via the Investors and Media section of 2seventy bio’s website at View Source A replay will be archived on 2seventy bio’s site for 30 days following the event.

On June 6, 2023, Sound Biopharmaceuticals reported that the Phase I clinical study of the company’s independently developed second-generation 4-1BB target agonist FTL001 monoclonal antibody injection successfully completed the enrollment and dosing of the first patient at the Affiliated Cancer Hospital of Chongqing University (Press release, Sound Biopharmaceuticals, JUN 6, 2023, View Source [SID1234645030]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This study is an open, multi-center, multi-cohort Phase I clinical study designed to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of FTL001 in subjects with advanced recurrent metastatic and refractory solid tumors. The clinical trial will be conducted simultaneously in multiple clinical research centers in China.

"We are very pleased to have successfully dosed the first patient of FTL001, which represents a major milestone in the clinical trial of Feitong Bio." Dr. Li Qing, founder and CEO of Feitong Bio, said: "Feitong Bio is committed to unmet clinical needs, and FTL001 is one of the key drugs in our product pipeline for malignant tumors. Through in-depth research on the mechanism of action of 4-1BB, we have developed a series of monoclonal antibody and bispecific antibody products around this target. The first patient dosing of FTL001 is undoubtedly a solid step for us to meet the needs of patients. Feitong Bio is full of confidence in the potential of the 4-1BB target, and will make every effort to efficiently promote the clinical progress of this project, bring substantial clinical benefits to patients with malignant tumors, and open up a new path for tumor immunotherapy."

▶ About F TL001 ◀

4-1BB (CD137), as a T cell co-stimulatory immune checkpoint molecule, is one of the most promising drug targets among members of the tumor necrosis factor receptor superfamily (TNFRSF). FTL001 is the world’s first clinical-stage epitope-specific 4-1BB humanized monoclonal antibody drug, and its binding epitope completely overlaps with the endogenous 4-1BB ligand: it can not only simulate the endogenous ligand to effectively activate T cells and kill tumors in a natural way, but also avoid systemic toxicity caused by excessive activation by blocking the activation amplification effect produced by the ligand, thereby achieving a balance between effectiveness and safety.

▶ About Non-Tong Biology ◀

Feitong Bio is an innovation-driven biopharmaceutical company initiated by a Nobel Prize-winning team, dedicated to the discovery and development of innovative drugs, as well as clinical research and commercialization on a global scale. With its outstanding scientific research and innovative drug development capabilities, the company aims to meet unmet clinical needs, has built various core technology platforms, and established a variety of original biomacromolecule drug product pipelines with great market potential.

On June 6, 2023 TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the "Company"), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported the pricing of its public offering of an aggregate of 2,000,000 shares of its common stock (or common stock equivalents), together with accompanying common stock warrants, at a public offering price of $3.50 per share (or common stock equivalent) and accompanying warrants (Press release, TransCode Therapeutics, JUN 6, 2023, View Source [SID1234632594]). Each share of common stock (or common stock equivalent) is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $3.25 per share. The Series A-1 warrants will be exercisable immediately and will expire three years from the date of issuance, and the Series A-2 warrants will be exercisable immediately and will expire three years from the date of issuance. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be $7 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The closing of the offering is expected to occur on or about June 9, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering, together with its existing funds, for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, including related investigational new drug (IND) enabling studies, for further research and development of our other therapeutic candidates, and for working capital and other general corporate purposes.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-272082), which was declared effective by the Securities and Exchange Commission (the "SEC") on June 6, 2023. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website at View Source and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.